Case Review Form

      * Denotes required field.


      * First Name

      * Last Name

      * Email Address

      * Phone Number

      Cell Phone Number

      Office Phone Number

      Street Address




      Zip Code

      Please provide the best method and times to contact you:

      Date of birth of injured person

      Name of drug:

      Date you started taking the drug (mm-yyyy):

      Date you stopped taking the drug (mm-yyyy):

      Please describe any side effects:

      Other Info:

      No Yes, I agree to the Parker & Waichman LLP disclaimers.Click here to review all.

      Yes, I would like to receive the Parker & Waichman LLP monthly newsletter, InjuryAlert.

      please do not fill out the field below.

Sulfonylurea Drugs Linked to Rising Risk of Death Among Type 2 Diabetes Patients

Filed September 27th, 2013 Laurie

Patients who take sulfonylureas as first-line therapy for type 2 diabetes face an increased risk for death over those who take the more traditional treatment metformin, according to a new study. A second study shows that the combination of metformin and a sulfonylurea is associated with a significantly increased risk for death compared with combination therapy with metformin and a dipeptidyl peptidase-4 (DPP-4) inhibitor (or “gliptin”).

Craig Curry, PhD, from the University of Cardiff, United Kingdom, said the findings should convince doctors and authors of clinical guidelines to stop prescribing sulfonylureas to diabetic patients. He presented the studies’ results at the European Association for the Study of Diabetes (EASD) 2013 meeting, according to

“I am bewildered it’s still being used,” Dr. Currie told Medscape Medical News. “People should avoid using a drug where the balance of evidence, at the moment, demonstrates that it kills people.”

According to Andreas Pfeiffer, MD, from Charité Universitätsmedizin, Berlin, Germany, who moderated the EASD press conference, sulfonylureas are prescribed as first-line therapy for type 2 diabetics about 15 percent of the time, though that number varies from country to country. Here in the U.S., and in Europe, the drugs are used second-line treatment in combination with metformin because they are very cheap and an established treatment course, reported.

Andreas Pfeiffer, MD, from Charité Universitätsmedizin, Berlin, Germany, who moderated the EASD press conference, told that the clinical guidelines highlight the potential dangers and benefits of sulfonylureas, but Germany and other healthcare systems require physicians to prescribe sulfonylureas if a patient can’t take Metformin or needs a second drug to treat his or her type 2 diabetes.

Be Sociable, Share!

Comments are closed.

Click Here Now, to Have an Attorney Answer Your
Medicinal Drug Injuries Questions
No Cost - No Obligation!